Dual GIP / GLP-1
Weekly injection

Maximus weight-loss program.

Mounjaro®

A once-weekly tirzepatide injection that activates two hormone receptors, GIP and GLP-1, to reduce appetite, slow gastric emptying, and support metabolic health. Prescribed by your Maximus clinician as part of a personalized weight-loss program.

*Mounjaro® is FDA-approved for type 2 diabetes, not for weight loss.

Eli Lilly states that Mounjaro® is not a weight loss drug. Some clinicians prescribe tirzepatide off-label as part of a weight-loss program. Your Maximus clinician will determine whether Mounjaro® is appropriate based on your medical history. If you'd prefer FDA-approved tirzepatide for weight loss, see Zepbound® KwikPen® → — same active ingredient, on-label for chronic weight management.

Personalized doses

View more pricing information →

Starting at $1,249.99/mo

No hidden fees
No membership

Free discreet shipping
FDA-approved
Board-certified doctors

Split your payment into manageable installments with Klarna.

Get started

Important: thyroid C-cell tumor risk. Mounjaro® may cause thyroid C-cell tumors. Do not use if you or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Medical consultation required to determine eligibility/if a prescription is clinically appropriate. Results may vary. For full details, important safety information, and restrictions visit: maximustribe.com/safety. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, and KwikPen® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. Maximus is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.

Get started

Weight Loss Protocol Mounjaro starting at $1,249.99/mo

Get started

Weight change observed across tirzepatide A1C trials.

Mounjaro® has not been studied specifically as a weight-loss medication. Across SURPASS-program studies of adults with type 2 diabetes designed to measure A1C reduction, mean body weight reductions were dose-dependent, ranging from 12 lb to 25 lb, qualified as a study observation tied to A1C trials.

Important · About these numbers. The weight numbers above are study observations from SURPASS-program trials designed to measure A1C reduction in adults with type 2 diabetes. Individual results vary. For tirzepatide outcomes from dedicated weight-loss trials, see Zepbound® KwikPen® →, FDA-approved for chronic weight management.

12-17 lb

Weight change · 5 mg

Mean body weight reduction observed in adults with type 2 diabetes across SURPASS A1C-focused trials.

SURPASS program · Eli Lilly · A1C trial

15-21 lb

Weight change · 10 mg

Mean body weight reduction observed in adults with type 2 diabetes on the 10 mg maintenance dose.

SURPASS program · Eli Lilly · A1C trial

17-25 lb

Weight change · 15 mg

Mean body weight reduction observed in adults with type 2 diabetes on the highest 15 mg dose across SURPASS A1C-focused trials.

SURPASS program · Eli Lilly · A1C trial

ACTIVE INGREDIENT: Tirzepatide

DELIVERY: Once-weekly injection

MECHANISM: Dual GIP / GLP-1

FDA-APPROVED USE: Type 2 diabetes

Get started

Dual receptor activation. Once weekly.

Tirzepatide is a single-molecule dual GIP and GLP-1 receptor agonist. It directly activates both GIP and GLP-1 pathways to regulate blood sugar, lower A1C, and improve metabolic markers. Appetite reduction and weight effects are secondary observations tied to A1C-trial populations on background diabetes therapy.

GIP receptor activation

Glucose-dependent insulinotropic polypeptide. The "second" incretin hormone, often paired with GLP-1 in the body's natural glucose response.

Once-weekly titration

Start at 2.5 mg for 4 weeks, then 5 mg. Step up to 10 or 15 mg as your clinician directs.

GLP-1 receptor activation

Helps regulate appetite, slow gastric emptying, and support insulin response — the same family of mechanisms behind semaglutide.

Side effects

Contact your provider immediately if you have these symptoms. Regular monitoring may be needed to track your response to treatment.

Common side effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain

Indigestion
Injection-site reactions
Feeling tired
Belching
Hair loss
Heartburn

Rare, but serious side effects may include:

Acute pancreatitis (including fatal, hemorrhagic, necrotizing)
Acute gallbladder disease
Acute kidney injury (typically secondary to dehydration)
Severe gastrointestinal disease / delayed gastric emptying
Hypoglycemia (especially with insulin or sulfonylureas)
Hypersensitivity reactions including anaphylaxis and angioedema
Pulmonary aspiration during anesthesia or deep sedation (delayed gastric emptying)
Suicidal behavior and ideation (monitor)
Diabetic retinopathy complications (in T2D clients with pre-existing retinopathy)
Thyroid C-cell tumors (rodent data). Boxed warning class effect: contraindicated in clients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Is Mounjaro® right for you?

Best for people who

T2D adults seeking blood sugar control
T2D adults whose clinician selects tirzepatide over semaglutide for mechanism reasons
Adults seeking tirzepatide-based weight management who specifically prefer the Mounjaro brand

Off-label weight management · Important disclosure

Mounjaro® is FDA-approved for type 2 diabetes, not for weight loss. Eli Lilly states that Mounjaro® is not a weight loss drug. Some clinicians prescribe tirzepatide off-label as part of a weight-loss program. Your Maximus clinician will determine whether Mounjaro® is appropriate based on your medical history. If you'd prefer FDA-approved tirzepatide for weight loss, see Zepbound® KwikPen® → — same active ingredient, on-label for chronic weight management.

Medical requirements

Not for clients with type 1 diabetes
No history of medullary thyroid carcinoma or MEN 2 syndrome
Not currently pregnant or breastfeeding
No severe gastrointestinal disease

It's easy to get started.

Complete your evaluation

Answer a few health questions online. Takes about 5 minutes. No appointment needed, no waiting rooms.

Physician review

A board-certified physician reviews your information and determines if tirzepatide is right for you.

Treatment delivered

If prescribed, your medication ships directly to your door in discreet, unmarked packaging.

Start my treatment

Weight Loss Treatment FAQs

Is Mounjaro®approved for weight loss?

No. Mounjaro® is FDA-approved for type 2 diabetes. Eli Lilly states that Mounjaro® is not a weight loss drug. Some clinicians prescribe tirzepatide off-label as part of a weight-loss program. Your Maximus clinician will determine whether Mounjaro® is appropriate based on your medical history. For FDA-approved tirzepatide for weight loss, see Zepbound® KwikPen® — same active ingredient, on-label for chronic weight management.

What's the difference between Mounjaro® and Zepbound®?

Both contain tirzepatide. Mounjaro® is FDA-approved for type 2 diabetes. Zepbound® is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same molecule, different indications, different dose ladders. The choice typically comes down to insurance coverage and clinical fit.

How much weight will I lose on Mounjaro®?

Mounjaro® has not been studied specifically as a weight-loss medication. In studies of adults with type 2 diabetes designed to measure A1C reduction, mean body weight reductions were 12–17 lb on 5 mg, 15–21 lb on 10 mg, and 17–25 lb on 15 mg. For tirzepatide outcomes from dedicated weight-loss trials, see Zepbound® KwikPen®, FDA-approved for chronic weight management. Individual results vary.

What does "dual GIP and GLP-1" mean?

Tirzepatide activates two hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are involved in your body's natural glucose and appetite regulation. Mounjaro® is the first single molecule to target both.

How is Mounjaro® taken?

Once-weekly subcutaneous self-injection on the same day each week. Start at 2.5 mg for 4 weeks (titration), then step up to 5 mg, 10 mg, or 15 mg. Your Maximus clinician will provide instructions.